Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

If you often have a difficult time breathing or if you suffer from a dry and persistent cough, you may be suffering from a condition known as interstitial lung disease. A Hauʻula teen's passion for a ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...

Dear Dr. Roach: My mother is 86 years old. She is in relatively good health. She recently saw her primary care physician for her routine checkup. Prior to her visit, she had developed cold symptoms.

Patients with inflammatory bowel disease (IBD) had a significantly higher risk for developing interstitial lung disease (ILD) compared with the general population and siblings who do not have the ...

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...